Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 98.26 Million USD | -34.46% |
| 2022 | 153.44 Million USD | 24.88% |
| 2021 | 129.18 Million USD | -42.83% |
| 2020 | 212.4 Million USD | 23.39% |
| 2019 | 180.41 Million USD | 7.52% |
| 2018 | 151.5 Million USD | 54.57% |
| 2017 | 107.67 Million USD | 83.91% |
| 2016 | 56.61 Million USD | 203.52% |
| 2015 | 21.76 Million USD | -25.47% |
| 2014 | -4.35 Million USD | 140.01% |
| 2013 | -83.68 Million USD | -44.04% |
| 2012 | -41.83 Million USD | -16.29% |
| 2011 | -36.72 Million USD | 4.08% |
| 2010 | -38.28 Million USD | -834.86% |
| 2009 | 5.21 Million USD | 121.99% |
| 2008 | -23.68 Million USD | -44.96% |
| 2007 | -16.34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 38.92 Million USD | 135.88% |
| 2024 Q3 | 40.84 Million USD | 67.08% |
| 2024 Q1 | 16.5 Million USD | -59.42% |
| 2023 Q2 | 5.29 Million USD | -81.63% |
| 2023 Q1 | 28.84 Million USD | -47.59% |
| 2023 FY | - USD | -34.46% |
| 2023 Q4 | 40.66 Million USD | 29.96% |
| 2023 Q3 | 31.29 Million USD | 490.6% |
| 2022 Q4 | 55.02 Million USD | 145.55% |
| 2022 FY | - USD | 24.88% |
| 2022 Q3 | 22.41 Million USD | -36.76% |
| 2022 Q1 | 37.97 Million USD | 79.72% |
| 2022 Q2 | 35.43 Million USD | -6.69% |
| 2021 Q2 | 33.9 Million USD | 40.94% |
| 2021 FY | - USD | -42.83% |
| 2021 Q4 | 21.13 Million USD | -48.43% |
| 2021 Q1 | 24.05 Million USD | -54.94% |
| 2021 Q3 | 40.97 Million USD | 20.87% |
| 2020 Q3 | 64.9 Million USD | 15.21% |
| 2020 FY | - USD | 23.39% |
| 2020 Q1 | 34.78 Million USD | -25.64% |
| 2020 Q2 | 56.33 Million USD | 61.94% |
| 2020 Q4 | 53.37 Million USD | -17.76% |
| 2019 Q2 | 42.59 Million USD | 67.52% |
| 2019 FY | - USD | 7.52% |
| 2019 Q1 | 25.42 Million USD | -42.69% |
| 2019 Q4 | 46.78 Million USD | 17.75% |
| 2019 Q3 | 39.72 Million USD | -6.74% |
| 2018 Q3 | 41.93 Million USD | 6.48% |
| 2018 Q2 | 39.38 Million USD | 20.81% |
| 2018 Q1 | 32.6 Million USD | -7.44% |
| 2018 Q4 | 44.36 Million USD | 5.8% |
| 2018 FY | - USD | 54.57% |
| 2017 Q4 | 35.22 Million USD | 52.1% |
| 2017 FY | - USD | 83.91% |
| 2017 Q3 | 23.15 Million USD | -13.35% |
| 2017 Q2 | 26.72 Million USD | 47.97% |
| 2017 Q1 | 18.06 Million USD | 8.2% |
| 2016 FY | - USD | 203.52% |
| 2016 Q2 | 10.8 Million USD | 91.41% |
| 2016 Q4 | 16.69 Million USD | -19.86% |
| 2016 Q3 | 20.82 Million USD | 92.76% |
| 2016 Q1 | 5.64 Million USD | -20.29% |
| 2015 Q4 | 7.08 Million USD | 57.97% |
| 2015 FY | - USD | -25.47% |
| 2015 Q3 | 4.48 Million USD | 38.45% |
| 2015 Q2 | 3.23 Million USD | -13.81% |
| 2015 Q1 | 3.75 Million USD | -22.52% |
| 2014 Q2 | 4.07 Million USD | 131.12% |
| 2014 Q1 | -13.09 Million USD | -16.39% |
| 2014 Q4 | 4.84 Million USD | -83.56% |
| 2014 FY | - USD | 140.01% |
| 2014 Q3 | 29.48 Million USD | 623.81% |
| 2013 FY | - USD | -44.04% |
| 2013 Q4 | -11.24 Million USD | 33.33% |
| 2013 Q3 | -16.87 Million USD | -9.34% |
| 2013 Q2 | -15.43 Million USD | 12.75% |
| 2013 Q1 | -17.68 Million USD | -39.18% |
| 2012 Q2 | -9.39 Million USD | -16.17% |
| 2012 Q1 | -8.09 Million USD | 59.17% |
| 2012 Q3 | -11.72 Million USD | -24.78% |
| 2012 Q4 | -12.7 Million USD | -8.37% |
| 2012 FY | - USD | -16.29% |
| 2011 Q3 | -9.95 Million USD | -22.55% |
| 2011 Q4 | -19.81 Million USD | -99.12% |
| 2011 Q1 | -9.14 Million USD | 52.15% |
| 2011 FY | - USD | 4.08% |
| 2011 Q2 | -8.12 Million USD | 11.23% |
| 2010 Q4 | -19.11 Million USD | 0.0% |
| 2010 FY | - USD | -834.86% |
| 2009 FY | - USD | 121.99% |
| 2009 Q4 | -13.43 Million USD | 0.0% |
| 2008 FY | - USD | -44.96% |
| 2007 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | 1052.816% |
| Harrow Health, Inc. | 9.72 Million USD | -910.614% |
| Dynavax Technologies Corporation | 9.66 Million USD | -916.574% |
| Biofrontera Inc. | -18.45 Million USD | 632.499% |
| Cronos Group Inc. | -72.14 Million USD | 236.193% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 2271.536% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 110.624% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 372.33% |
| RedHill Biopharma Ltd. | 26.26 Million USD | -274.101% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 13923.169% |
| Radius Health, Inc. | 38.31 Million USD | -156.492% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 3156.295% |
| DURECT Corporation | -24.68 Million USD | 498.08% |
| ProPhase Labs, Inc. | -14.82 Million USD | 762.723% |
| Safety Shot Inc | -12.18 Million USD | 906.406% |
| Phibro Animal Health Corporation | 84.6 Million USD | -16.139% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 4279.565% |
| Alvotech | -484.86 Million USD | 120.266% |
| Assertio Holdings, Inc. | -222.44 Million USD | 144.173% |
| Rockwell Medical, Inc. | -4.69 Million USD | 2193.353% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2669.332% |
| Procaps Group S.A. | 104.02 Million USD | 5.542% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 161.857% |
| SCYNEXIS, Inc. | 73.47 Million USD | -33.728% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 9809.684% |
| Viatris Inc. | 3.51 Billion USD | 97.206% |
| OptiNose, Inc. | -15.55 Million USD | 731.788% |
| SIGA Technologies, Inc. | 84.15 Million USD | -16.757% |
| Tilray Brands, Inc. | -72.84 Million USD | 234.896% |
| PetIQ, Inc. | 81.48 Million USD | -20.588% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 2669.332% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 76.385% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 2605.179% |
| Alimera Sciences, Inc. | 7.27 Million USD | -1250.495% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 68.131% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1238.699% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 2562.306% |
| Organogenesis Holdings Inc. | 36.03 Million USD | -172.715% |
| Journey Medical Corporation | 1.92 Million USD | -5015.148% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 2432.977% |
| Alpha Teknova, Inc. | -25.53 Million USD | 484.753% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 684.754% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -12001.232% |
| PainReform Ltd. | -9.56 Million USD | 1126.878% |
| Cosmos Health Inc. | -17.06 Million USD | 675.918% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 165.892% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 1269.646% |
| Embecta Corp. | 245.4 Million USD | 59.958% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 2816.2% |
| Talphera, Inc. | -9.84 Million USD | 1098.395% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 39.678% |
| Incannex Healthcare Limited | -18.5 Million USD | 631.031% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 590.555% |
| Shineco, Inc. | -26.55 Million USD | 470.047% |
| Procaps Group, S.A. | 104.02 Million USD | 5.542% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 10.115% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -8213.198% |
| Lantheus Holdings, Inc. | 491 Million USD | 79.988% |
| Alvotech | -484.86 Million USD | 120.266% |
| Hempacco Co., Inc. | -12.77 Million USD | 869.278% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | -26.786% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 165.461% |
| Kamada Ltd. | 21.53 Million USD | -356.311% |
| Indivior PLC | 66 Million USD | -48.882% |
| Evoke Pharma, Inc. | -7.29 Million USD | 1447.477% |
| Flora Growth Corp. | -45.87 Million USD | 314.218% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 590.555% |
| Evolus, Inc. | -41.81 Million USD | 335.02% |
| HUTCHMED (China) Limited | 25.52 Million USD | -284.919% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 59.306% |
| Akanda Corp. | -27.73 Million USD | 454.28% |